Stronger Sell Today AGRX ranks #4060 as SELL CANDIDATE #4060 Weaker Sell

AGRX stock forecast Agile Therapeutics

AGRX stock forecast





AGRX Forecast and Technical Stock Analysis

Sell candidate since 2019-07-16

Agile Therapeutics fell by -1.54% in the last day ( Friday, 19th Jul 2019 ) from $1.30 to $1.28 During day the stock fluctuated 9.11% from a day low at $1.23 to a day high of $1.34. The price has fallen in 6 of the last 10 days and is down by -16.34% for this period. Volume has increased in the last day by 101 009 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 183 284 shares bought and sold for approximately $234 604.00.

Quick summary:

  • 30 day high of the AGRX stock price was $1.64 and low was $1.23.
  • 90 day high was $1.64 and low was $1.02.
  • 52 week high for the Agile Therapeutics - $1.70 and low - $0.23.
Top Trending Stocks


Agile Therapeutics lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -4.52% during the next 3 months and, with 90% probability hold a price between $0.95 and $1.48 at the end of this period.

Top Golden Star Stocks


A buy signal was issued from a pivot bottom point on Tuesday July 16, 2019, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Agile Therapeutics holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $1.31 and $1.35. A break-up above any of these levels will issue buy signals. Agile Therapeutics gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".

Relative Strength Index (RSI)

RSImin/max Values: [ 20 - 75 ]

RSI14 is 34 and the stock is currently not being overbought or oversold

* uses dynamical calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Support & Resistance

Agile Therapeutics finds support from accumulated volume at $1.27.

Support: $1.27 Price: $1.28 Resistance: $1.38


This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.11 between high and low, or 9.11%. For the last week, the stock has had a daily average volatility of 7.39%.

Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.

7.39 %

Average volatility

Overall risk:

Very Low Low Medium High Very High

Sell Candidate Downgraded


Agile Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Stronger Sell Today AGRX ranks #4060 as SELL CANDIDATE #4060 Weaker Sell

Will AGRX stock price go up or down on Mon, 22 Jul 2019?

Trading With Moving Average
As an investor, you always seek to understand what other... Full Article
Pivot Points
Pivot Points refer to points of significant change. As a... Full Article
Accumulated Volume - Support and Resistance
Volume is perhaps the best indicator of all and should... Full Article
Volume - The Indicator You Really Need to Know
Many new traders getting into the world of technical analysis... Full Article
We Give Back!
In 2016 donated to NGO Goodwill projects to help purchase medical... Full Article
Better Buy: Amazon vs. Facebook
Amazon's stock slipped 21% over the past six months, as... Full Article

Proudly made at